Nyrada – Cholesterol-Lowering Program Update
• Cholesterol-Lowering Program preclinical safety and toxicology studies remain on track to commence Q3 CY2022 • COVID-related lockdowns in Shanghai… Read more
• Cholesterol-Lowering Program preclinical safety and toxicology studies remain on track to commence Q3 CY2022 • COVID-related lockdowns in Shanghai… Read more
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation that will be… Read more
• Brain Injury Program target revealed as versatile TRPC ion channels • NYR-BI02 is a potent blocker of three TRPC… Read more
The European Patent Office has issued a Notice of Intention to grant Nyrada’s patent application for novel compounds inhibiting PCSK9…. Read more
Highlights: • Brain Injury Program: – Exploratory study shows new lead drug candidate NYR-BI02 could be taken orally, offers potential… Read more
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation ahead of a… Read more
Nyrada Inc. (ASX: NYR) released an announcement about its new lead brain injury drug candidate NYR-BI02. The new drug shows… Read more
Highlights: • Research and development costs of $1.13M as Nyrada’s lead preclinical programs advance (1H FY2021: $1.05M) • Robust cash… Read more
Highlights: • Cholesterol-Lowering Program: – Charles River Laboratories appointed to conduct safety pharmacology and toxicology studies in Nyrada’s cholesterol-lowering drug… Read more